No photo of Marco Pravetoni
Contact Expert

View Scopus Profile

Marco Pravetoni

PhD

20022021

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

  • 1 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components

Pravetoni, M.

Research Foundation for Mental Hygiene

9/1/19 → 8/31/20

Project: Research project

    • Novel nanovaccines against opioid use disorder

    Pravetoni, M. & Birnbaum, A. K.

    VIRGINIA POLYTECHNIC INST. & STATE UNIV.

    7/15/19 → 6/30/21

    Project: Research project

    • Development of TRAC-478: A Synthetic Dual TLR Adjuvant Combination System

    Pravetoni, M.

    University of Montana

    7/1/19 → 6/30/21

    Project: Research project

    • Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components

    Pravetoni, M.

    Research Foundation for Mental Hygiene

    6/3/19 → 8/31/20

    Project: Research project

    • Vaccines for fentanyl and its derivatives: A strategy to reduce illicit use and overdose

    Pravetoni, M. & Birnbaum, A. K.

    NIH NIDA NATL INST ON DRUG AB

    2/1/19 → 1/31/21

    Project: Research project

    • Research Output

    A fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats

    Raleigh, M. D., Baruffaldi, F., Peterson, S. J., Le Naour, M., Harmon, T. M., Vigliaturo, J. R., Pentel, P. R. & Pravetoni, M., Feb 2019, In : Journal of Pharmacology and Experimental Therapeutics. 368, 2, p. 282-291 10 p.

    Research output: Contribution to journal › Article

    Open Access
    • 6 Scopus citations

    Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders

    Robinson, C., Baehr, C., Schmiel, S. E., Accetturo, C., Mueller, D. L. & Pravetoni, M., Apr 3 2019, In : Human Vaccines and Immunotherapeutics. 15, 4, p. 909-917 9 p.

    Research output: Contribution to journal › Article

    • 1 Scopus citations

    Covalent Poly(lactic acid) Nanoparticles for the Sustained Delivery of Naloxone

    Kassick, A. J., Allen, H. N., Yerneni, S. S., Pary, F., Kovaliov, M., Cheng, C., Pravetoni, M., Tomycz, N. D., Whiting, D. M., Nelson, T. L., Feasel, M., Campbell, P. G., Kolber, B. & Averick, S., Aug 19 2019, In : ACS Applied Bio Materials. 2, 8, p. 3418-3428 11 p.

    Research output: Contribution to journal › Article

    • 2 Scopus citations

    Development of vaccines to treat opioid use disorders and reduce incidence of overdose

    Pravetoni, M. & Comer, S. D., Nov 1 2019, In : Neuropharmacology. 158, 107662.

    Research output: Contribution to journal › Review article

    • 2 Scopus citations

    Formulation and Characterization of Conjugate Vaccines to Reduce Opioid Use Disorders Suitable for Pharmaceutical Manufacturing and Clinical Evaluation

    Baruffaldi, F., Raleigh, M. D., King, S. J., Roslawski, M. J., Birnbaum, A. K., Hassler, C., Carroll, F. I., Runyon, S. P., Winston, S., Pentel, P. R. & Pravetoni, M., Jun 3 2019, In : Molecular pharmaceutics. 16, 6, p. 2364-2375 12 p.

    Research output: Contribution to journal › Article

    • 1 Scopus citations